Table 2.
Cox proportional hazards regression analysis of progression-free survival.
| HR (95% CI) | P-value | ||
|---|---|---|---|
| Age (years) | > 65 years vs. < 65 years | 1.09 (0.63–1.87) | 0.759 |
| Sex | Male vs. Female | 0.99 (0.63–1.55) | 0.963 |
| Brain metastasis | Presence vs. Absence | 1.69 (1.06–2.70) | 0.028 |
| Performance status | ECOG ≥ 2 vs. 0–1 | 1.66 (0.85–3.25) | 0.138 |
| EGFR mutation | Exon 19 deletion vs. Others | 0.97 (0.60–1.57) | 0.908 |
| PD-L1 level | ≥ 50% vs. < 1% | 1.42 (0.73–2.76) | 0.300 |
| 1–49% vs. < 1% | 1.17 (0.68–2.01) | 0.576 | |
| E-cadherin | Loss vs. preserved | 1.33 (0.69–2.56) | 0.393 |
| MET | Presence vs. absence | 1.00 (0.62–1.62) | 0.989 |
| p-STAT3 | Presence vs. absence | 0.78 (0.48–1.29) | 0.337 |
| p-AKT | Presence vs. absence | 1.08 (0.64–1.83) | 0.767 |
| BIM | Presence vs. absence | 2.94 (1.41–6.14) | 0.004 |
EGFR, epidermal growth factor receptor.